{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:40:09Z","timestamp":1748565609218,"version":"3.41.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"SPARKS Medical Charity for Children\u2019s Health"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.jpba.2015.08.011","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T19:00:16Z","timestamp":1439492416000},"page":"276-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Urinary excretion and metabolism of miglustat and valproate in patients with Niemann\u2013Pick type C1 disease: One- and two-dimensional solution-state 1 H NMR studies"],"prefix":"10.1016","volume":"117","author":[{"given":"Fay","family":"Probert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Ruiz-Rodado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle te","family":"Vruchte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim D.W.","family":"Claridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Edgar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Zonato","family":"Tocchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin H.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-3734","authenticated-orcid":false,"given":"Martin","family":"Grootveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.08.011_bib0005","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann\u2013Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jpba.2015.08.011_bib0010","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann\u2013Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpba.2015.08.011_bib0015","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/ajmg.a.31735","article-title":"The National Niemann\u2013Pick C1 disease database: report of clinical features and health problems","volume":"143A","author":"Garver","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.jpba.2015.08.011_bib0020","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-36","article-title":"Miglustat therapy in the French cohort of paediatric patients with Niemann\u2013Pick disease type C","volume":"7","author":"Heron","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jpba.2015.08.011_bib0025","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/NEN.0b013e31825414a6","article-title":"Miglustat improves purkinje cell survival and alters microglial phenotype in feline Niemann\u2013Pick disease type C","volume":"71","author":"Stein","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jpba.2015.08.011_bib0030","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0957-4166(99)00468-1","article-title":"Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis","volume":"11","author":"Butters","year":"2000","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jpba.2015.08.011_bib0035","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","article-title":"Critical role for glycosphingolipids in Niemann\u2013Pick disease type C","volume":"11","author":"Zervas","year":"2001","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jpba.2015.08.011_bib0040","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann\u2013Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jpba.2015.08.011_bib0045","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.pediatrneurol.2012.04.005","article-title":"Early miglustat therapy in infantile Niemann\u2013Pick disease type C","volume":"47","author":"Di Rocco","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jpba.2015.08.011_bib0050","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ymgme.2009.07.003","article-title":"Miglustat in patients with Niemann\u2013Pick disease Type C (NP-C): a multicenter observational retrospective cohort study","volume":"98","author":"Pineda","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jpba.2015.08.011_bib0055","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ijdevneu.2012.07.002","article-title":"Oxidative stress in Niemann\u2013Pick type C patients: a protective role of N-butyl-deoxynojirimycin therapy","volume":"30","author":"Ribas","year":"2012","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.jpba.2015.08.011_bib0060","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ymgme.2010.06.018","article-title":"Oxidative stress in Niemann\u2013Pick disease, type C","volume":"101","author":"Fu","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jpba.2015.08.011_bib0065","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/8904_2011_47","article-title":"Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in Niemann\u2013Pick type C","volume":"3","author":"Mattsson","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.jpba.2015.08.011_bib0070","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0883073809344222","article-title":"Long-term miglustat therapy in children with Niemann\u2013Pick disease type C","volume":"25","author":"Patterson","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jpba.2015.08.011_bib0075","doi-asserted-by":"publisher","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2015.08.011_bib0080","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2015.08.011_bib0085","first-page":"472","article-title":"Miglustat. Oxford glycosciences\/actelion","volume":"4","author":"Lachmann","year":"2003","journal-title":"Curr. Opin. Investig Drugs"},{"year":"2013","series-title":"100mg Hard Capsules: Summary of Product Characteristics","author":"Zavesca","key":"10.1016\/j.jpba.2015.08.011_bib0090"},{"key":"10.1016\/j.jpba.2015.08.011_bib0095","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jpba.2011.10.016","article-title":"Validated LC\u2013MS\/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic study","volume":"59","author":"Spieker","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.08.011_bib0100","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jchromb.2008.11.040","article-title":"Rapid quantification of miglustat in human plasma and cerebrospinal fluid by liquid chromatography coupled with tandem mass spectrometry","volume":"877","author":"Guitton","year":"2009","journal-title":"J. Chromatogr. B. Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2015.08.011_bib0105","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1021\/cr990292q","article-title":"Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders","volume":"100","author":"Butters","year":"2000","journal-title":"Chem Rev."},{"key":"10.1016\/j.jpba.2015.08.011_bib0110","doi-asserted-by":"publisher","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.jpba.2015.08.011_bib0115","unstructured":"T.D. Butters, R.A., Dwek, G.W.J., Fleet, M.G., Orchard, F.M. Platt, Pharmaceutically active piperidine derivatives, Patent Number: US 8729099, Official Gazette of the United States Patent and Trademark Office Patents Published: May 2 (2014)."},{"key":"10.1016\/j.jpba.2015.08.011_bib0120","unstructured":"T. Wennekes, Chapter 3: Improving Glycemic Control with Lipophilic Iminosugars. In: Lipophilic iminosugars: synthesis and evaluation as inhibitors of glucosylceramide metabolism (2008)."},{"key":"10.1016\/j.jpba.2015.08.011_bib0125","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1042\/bj20020466","article-title":"Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins","volume":"366","author":"Mellor","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.jpba.2015.08.011_bib0130","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-013-0164-6","article-title":"Miglustat: a review of its use in Niemann\u2013Pick disease type C","volume":"74","author":"Lyseng-Williamson","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2015.08.011_bib0135","first-page":"177","article-title":"Valproic acid intoxication identified by 1H and 1H-(13)C correlated NMR spectroscopy of urine samples","volume":"10","author":"Azaroual","year":"2000","journal-title":"MAGMA"},{"key":"10.1016\/j.jpba.2015.08.011_bib0140","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1021\/ac048630x","article-title":"Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets","volume":"77","author":"Cloarec","year":"2005","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2015.08.011_bib0145","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/2213235X02666141112215616","article-title":"1H NMR-linked urinary metabolic profiling of Niemann\u2013Pick class C1 (NPC1) disease: identification of potential new biomarkers using correlated component regression (CCR) and genetic algorithm (GA) analysis strategies","volume":"2","author":"Ruiz-Rodado","year":"2014","journal-title":"Curr. Metabolomics"},{"key":"10.1016\/j.jpba.2015.08.011_bib0150","doi-asserted-by":"publisher","first-page":"W127","DOI":"10.1093\/nar\/gks374","article-title":"MetaboAnalyst 2.0\u2014a comprehensive server for metabolomic data analysis","volume":"40","author":"Xia","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2015.08.011_bib0155","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2174\/2213235X11301020005","article-title":"muma, An r package for metabolomics univariate and multivariate statistical analysis muma, an r package for metabolomics univariate and multivariate statistical analysis","volume":"1","author":"Gaude","year":"2013","journal-title":"Curr. Metabolomics"},{"key":"10.1016\/j.jpba.2015.08.011_bib0160","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0090-9556(24)15100-8","article-title":"In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin","volume":"28","author":"Fisher","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2015.08.011_bib0165","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/1471-2105-11-362","article-title":"Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse","volume":"11","author":"Carlsson","year":"2010","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.jpba.2015.08.011_bib0170","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1124\/dmd.30.6.694","article-title":"Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance","volume":"30","author":"Kemp","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2015.08.011_bib0175","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0009-8981(03)00221-3","article-title":"Direct observation of 3-keto-valproate in urine by 2D-NMR spectroscopy","volume":"334","author":"Meshitsuka","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2015.08.011_bib0180","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.nbd.2004.05.002","article-title":"Treatment with miglustat reverses the lipid-trafficking defect in Niemann\u2013Pick disease type C","volume":"16","author":"Lachmann","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jpba.2015.08.011_bib0185","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2015.08.011_bib0190","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1528-1157.1992.tb02301.x","article-title":"Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity","volume":"33","author":"Fisher","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2015.08.011_bib0195","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.510230418","article-title":"Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions","volume":"23","author":"Booth","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.08.011_bib0200","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jchromb.2011.05.022","article-title":"LC\u2013MS\/MS method for simultaneous determination of valproic acid and major metabolites in human plasma","volume":"879","author":"Gao","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2015.08.011_bib0205","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2015.08.011_bib0210","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jflm.2011.06.003","article-title":"An UPLC\u2013MS\/MS method for the determination of valproic acid in blood of a fatal intoxication case","volume":"18","author":"Proenca","year":"2011","journal-title":"J. Forensic Leg. Med."},{"key":"10.1016\/j.jpba.2015.08.011_bib0215","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.seizure.2011.10.002","article-title":"Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy","volume":"21","author":"Chen","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.jpba.2015.08.011_bib0220","doi-asserted-by":"publisher","first-page":"37547","DOI":"10.1074\/jbc.M506683200","article-title":"Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus","volume":"280","author":"Chen","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2015.08.011_bib0225","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pnmrs.2005.03.001","article-title":"Cryogenically cooled probes\u2014a leap in NMR technology","volume":"46","author":"Kovacsa","year":"2005","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515301096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515301096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:13:06Z","timestamp":1748563986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515301096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":45,"alternative-id":["S0731708515301096"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.011","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary excretion and metabolism of miglustat and valproate in patients with Niemann\u2013Pick type C1 disease: One- and two-dimensional solution-state 1H NMR studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}